• 1. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 2. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 3. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 4. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565
• 5. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles 2,4,5-trisubstituted thiazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Thiazoles 2,4,5-trisubstituted thiazoles

Research Brief on 2-Cyano-4,5-dimethylthiazole (CAS: 1378802-88-0) in Chemical Biology and Pharmaceutical Applications

2-Cyano-4,5-dimethylthiazole (CAS: 1378802-88-0) has recently emerged as a compound of significant interest in chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. This heterocyclic thiazole derivative, characterized by its cyano and dimethyl functional groups, exhibits unique physicochemical properties that make it a valuable scaffold for designing novel bioactive molecules. Recent studies have highlighted its potential as a key intermediate in synthesizing kinase inhibitors, antimicrobial agents, and anti-inflammatory compounds.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 2-Cyano-4,5-dimethylthiazole as a core structure in developing selective JAK3 inhibitors. The researchers utilized structure-activity relationship (SAR) analysis to optimize the compound's interactions with the ATP-binding site of JAK3, achieving nanomolar potency while maintaining selectivity over other JAK isoforms. The CAS: 1378802-88-0 derivative showed promising results in preclinical models of autoimmune disorders, with improved metabolic stability compared to earlier thiazole-based inhibitors.

In antimicrobial research, a team from the University of Cambridge reported in ACS Infectious Diseases (2024) that derivatives of 2-Cyano-4,5-dimethylthiazole exhibited potent activity against drug-resistant Gram-positive pathogens, including MRSA and VRE. The electron-withdrawing cyano group was found to enhance membrane permeability, while the dimethyl substitution pattern contributed to reduced cytotoxicity against mammalian cells. Molecular docking studies revealed that these compounds interfere with bacterial cell wall biosynthesis by targeting undecaprenyl pyrophosphate synthase (UPPS).

The compound's role in cancer therapeutics has also been explored. A Nature Communications paper (2023) described how 1378802-88-0-based small molecules can modulate the tumor microenvironment by inhibiting indoleamine 2,3-dioxygenase (IDO1), a key enzyme in tryptophan metabolism associated with immune evasion in cancers. The thiazole core provided optimal spacing between the catalytic heme-binding moiety and allosteric regulatory sites, leading to dual-mode inhibition with improved pharmacokinetic profiles.

From a synthetic chemistry perspective, recent advances in continuous flow chemistry have enabled more efficient production of 2-Cyano-4,5-dimethylthiazole derivatives. A Green Chemistry publication (2024) detailed a solvent-free, catalytic method for large-scale synthesis using immobilized Lewis acid catalysts, achieving >90% yield with minimal purification steps. This technological improvement addresses previous challenges in manufacturing consistency for preclinical and clinical supplies.

Looking forward, the unique properties of 2-Cyano-4,5-dimethylthiazole position it as a promising scaffold for addressing multiple therapeutic challenges. Current research directions include exploring its application in PROTAC design (where its small size and polarity are advantageous) and as a fluorescent probe for bioimaging due to its inherent photophysical characteristics. However, further optimization of metabolic stability and in vivo distribution profiles remains an active area of investigation for this compound class.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)